骨髓系衍生抑制细胞在前列腺癌中促进治疗诱导的耐药性
Anlin Liu1, Pan Song1, Zhenghuan Liu1
1Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
International journal of surgery (London, England)
|January 28, 2026
概括
骨髓原抑制细胞 (MDSCs) 驱动对前列腺癌 (PCa) 治疗的耐药性,如安卓素剥夺疗法 (ADT). 向MDSC可能会提高晚期PCa的免疫疗法的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 雄激素剥夺疗法 (ADT) 是前列腺癌 (PCa) 的标准,但耐药性导致割耐药PCa (CRPC).
- 瘤免疫微环境显著影响PCa治疗反应和预后.
- 骨髓原抑制细胞 (MDSC) 在PCa中积聚,形成一种免疫抑制环境,促进治疗失败和进展.
研究的目的:
- 审查MDSCs在推动前列腺癌治疗耐药性的作用.
- 探索针对MDSC的策略,以克服PCa.中的治疗耐药性.
- 评估将MDSC向疗法与免疫疗法结合用于改善PCa结果的潜力.
主要方法:
- 对前列腺癌中MDSCs研究的文献综述.
- 分析MDSCs对割抗性的贡献机制.
- 检查针对MDSC的当前和潜在的治疗策略.
主要成果:
- 在PCa中MDSC的积累会产生一种免疫抑制的瘤微环境.
- MDSC与瘤细胞的相互作用促进割抵抗和瘤的进展.
- 准MDSC为克服对ADT和其他疗法的耐药性提供了希望.
结论:
- MDSCs是前列腺癌治疗耐药性的关键参与者.
- 旨在调节MDSC活动,成熟或亡的策略是有希望的.
- 将MDSC向疗法与免疫疗法相结合可能会提高PCa的治疗疗效和患者存活率.
更多相关视频
相关概念视频
Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.8K
Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
Gene Therapy
27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
The Eukaryotic Promoter Region
18.8K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
18.8K


